Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights


2. Assumptions and Research Methodology


3. Executive Summary : Global Hepatitis Therapeutics Market


4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis


5. Market Outlook
5.1.Pipeline Analysis
5.2.New Product Launch, Approvals & Patent Expiry
5.3.Regulatory Scenario


6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Disease Type, 2016–2026
6.2.1. Hepatitis A
6.2.2. Hepatitis B
6.2.3. Hepatitis C
6.2.4. Others
6.3. Market Attractiveness, by Disease Type


7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class
7.1. Introduction & Definition
7.2. Market Value Forecast, by Drug Class, 2016–2026
7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.2.2. NS5A Inhibitor
7.2.3. Multi Class Combination
7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.2.5. Interferon & Ribavirin
7.2.6. Others
7.3. Market Attractiveness, by Drug Class


8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2016–2026
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel


9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
9.1. Market Value Forecast, by Region
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Market Attractiveness, by Country/Region


10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Disease Type, 2016–2026
10.2.1. Hepatitis A
10.2.2. Hepatitis B
10.2.3. Hepatitis C
10.2.4. Others
10.3.Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.3.2. NS5A Inhibitor
10.3.3. Multi Class Combination
10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.3.5. Interferon & Ribavirin
10.3.6. Others
10.4.Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5.Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6.Market Attractiveness, Analysis
10.6.1.By Disease Type
10.6.2. B Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country


11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Disease, 2016–2026
11.2.1. Hepatitis A
11.2.2. Hepatitis B
11.2.3. Hepatitis C
11.2.4. Others
11.3.Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.3.2. NS5A Inhibitor
11.3.3. Multi-class Combination
11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.3.5. Interferon & Ribavirin
11.3.6. Others
11.4.Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5.Market Value Forecast, by Country, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness, Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country


12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Disease Type, 2016–2026
12.2.1. Hepatitis A
12.2.2. Hepatitis B
12.2.3. Hepatitis C
12.2.4. Others
12.3.Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.3.2. NS5A Inhibitor
12.3.3. Multi-class Combination
12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.3.5. Interferon & Ribavirin
12.3.6. Others
12.4.Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Value Forecast, by Country, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness, Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country


13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Disease Type, 2016–2026
13.2.1. Hepatitis A
13.2.2. Hepatitis B
13.2.3. Hepatitis C
13.2.4. Others
13.3.Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.3.2. NS5A Inhibitor
13.3.3. Multi-class Combination
13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.3.5. Interferon & Ribavirin
13.3.6. Others
13.4.Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Value Forecast, by Country, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness, Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country

14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1.Introduction
14.2.Market Value Forecast, by Disease Type, 2016–2026
14.2.1. Hepatitis A
14.2.2. Hepatitis B
14.2.3. Hepatitis C
14.2.4. Others
14.3.Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.3.2. NS5A Inhibitor
14.3.3. Multi-class Combination
14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.3.5. Interferon & Ribavirin
14.3.6. Others
14.4.Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5.Market Value Forecast, by Country, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.5. Rest of Middle East & Africa
14.6.Market Attractiveness, Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country


15. Competition Landscape
15.1.Market Share Analysis, by Company (2017)
15.2. Company Profiles
15.2.1. Gilead Sciences, Inc.
15.2.2. F. Hoffmann-La Roche, Ltd.
15.2.3. Bristol Myers Squibb
15.2.4. Merck & Co., Inc.
15.2.5. AbbVie Inc.
15.2.6. NATCO Pharma Limited
15.2.7. Zydus Cadila
15.2.8. Hetero Healthcare Limited
15.2.9. LAURUS Labs
15.2.10. Cipla, Inc.



List of Figures



Figure 01: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
Figure 03: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
Figure 04: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 05: Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
Figure 06: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 07: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016–2026
Figure 08: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016–2026
Figure 09: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016–2026
Figure 10: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11: Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018–2026
Figure 12: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 13: Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 14: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016–2026
Figure 15: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016–2026
Figure 16: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016–2026
Figure 17: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016–2026
Figure 18: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016–2026
Figure 19: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 20: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 21: Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 22: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 23: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 24: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 25: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
Figure 26: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 27: North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 29: North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018–2026
Figure 30: North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 31: North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 32: North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 33: North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 34: North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 35: North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 38: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 39: Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 40: Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 41: Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 42: Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 43: Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 44: Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 46: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 47: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 48: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 49: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 50: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 51: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 52: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 53: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 54: Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 56: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 57: Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 58: Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 59: Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 60: Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 61: Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 62: Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 64: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 65: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 66: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 67: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 68: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 69: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 70: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 71: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 72: Global Hepatitis Therapeutics Market Share, by Company, 2017

 

List of Tables



Table 01: Pipeline Analysis
Table 02: Pipeline Analysis
Table 03: Pipeline Analysis
Table 04: New Product Launch, Approvals & Patent Expiry
Table 05: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026 2016–2026
Table 06: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 07: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 08: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 09: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 10: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 11: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 12: North America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 13: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 14: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 15: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 16: Europe Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 17: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 18: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 19: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 20: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 21: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 22: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 23: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 24: Latin America Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026
Table 25: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016 – 2026
Table 26: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Disease Type, 2016 – 2026
Table 27: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016 – 2026
Table 28: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2016 – 2026